Anti–Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

Abstract

I read the conclusion of the article by Maggio and colleagues 1 Maggio E. Sartore M. Attanasio M. Maraone G. Guerriero M. Polito A. Pertile G. Anti–vascular endothelial growth factor treatment for diabetic macular edema in a real-world clinical setting. Am J Ophthalmol. 2018; 195: 209-222 Abstract Full Text Full Text PDF Scopus (36) Google Scholar with great interest. They suggest an early switch to other treatment where anti–vascular endothelial growth factor (VEGF) therapy is ineffective for diabetic macular edema (DME). 1 Maggio E. Sartore M. Attanasio M. Maraone G. Guerriero M. Polito A. Pertile G. Anti–vascular endothelial growth factor treatment for diabetic macular edema in a real-world clinical setting. Am J Ophthalmol. 2018; 195: 209-222 Abstract Full Text Full Text PDF Scopus (36) Google Scholar Their impression resonates with experience elsewhere in the world. Anti–Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical SettingAmerican Journal of OphthalmologyVol. 195PreviewTo report the long-term outcomes of intravitreal anti–vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME) in a real-world clinical setting and to assess the efficacy of subsequent alternative treatments in eyes with suboptimal response to anti-VEGF. Full-Text PDF ReplyAmerican Journal of OphthalmologyVol. 199PreviewWe thank Dr. Gandhi for the interest in our work and for the valuable observation regarding the management of refractory diabetic macular edema (DME).1 Full-Text PDF